# Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)

> **NCT03403686** · — · RECRUITING · sponsor: **University of Alabama at Birmingham** · enrollment: 104 (estimated)

## Conditions studied

- Diabetic Retinopathy

## Interventions

- **BIOLOGICAL:** blood draw

## Key facts

- **NCT ID:** NCT03403686
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2018-01-11
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 104 (ESTIMATED)
- **Last updated:** 2025-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03403686

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03403686, "Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03403686. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*